These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 9013228

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 8. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 9. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufman L.
    Acta Urol Belg; 1997 Oct 15; 65(3):63-71. PubMed ID: 9421938
    [Abstract] [Full Text] [Related]

  • 10. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
    Shimada M, Uchida H, Kasahara T, Fuji K, Ogawa Y, Yoshida H, Hamajima T, Matsuda N, Ikeuchi T, Kai Y, Hiramori M, Hoshino M, Inoue K, Higaki Y.
    Hinyokika Kiyo; 1998 Jul 15; 44(7):525-32. PubMed ID: 9752613
    [Abstract] [Full Text] [Related]

  • 11. [Determination of free type and complex type prostate-specific antigen (PSA): differences in immunorecognition by Delfia PSA, ACS-PSA and Eiken PA kits].
    Sumi S, Umeda H, Koga F, Yano M, Imai T, Hosoya Y, Honda M, Maeda S, Suzuki T, Yoshida K, Negishi T.
    Hinyokika Kiyo; 1996 Apr 15; 42(4):279-84. PubMed ID: 8693960
    [Abstract] [Full Text] [Related]

  • 12. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 15; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 13. [Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade].
    Regueiro López JC, Ruiz Alvarez Cienfuegos F, Leva Vallejo M, Requena Tapia MJ, Merchan García JA, Prieto Castro R, Alvarez Kindelan J.
    Actas Urol Esp; 1995 May 15; 19(5):357-62. PubMed ID: 8659288
    [Abstract] [Full Text] [Related]

  • 14. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T, Aizawa T, Yamamoto S, Ohkubo Y, Tsujino S, Miki M.
    Hinyokika Kiyo; 1998 Jul 15; 44(7):477-80. PubMed ID: 9752601
    [Abstract] [Full Text] [Related]

  • 15. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
    Sekido N, Kawai K, Akaza H, Koiso K.
    Jpn J Clin Oncol; 1995 Aug 15; 25(4):164-7. PubMed ID: 7545251
    [Abstract] [Full Text] [Related]

  • 16. [The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method].
    Arai K, Honda M, Hosoya Y, Sumi S, Umeda H, Yoshida K.
    Rinsho Byori; 1996 Apr 15; 44(4):345-50. PubMed ID: 8847816
    [Abstract] [Full Text] [Related]

  • 17. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S.
    Hinyokika Kiyo; 1998 Aug 15; 44(8):557-63. PubMed ID: 9783191
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M, Carlström K, Rozell BL, Stege R, Pousette A.
    Clin Cancer Res; 2000 May 15; 6(5):1790-5. PubMed ID: 10815899
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.